All In Biotech

Drug Trial Radar · NCT04895241

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 548 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

548

Actual

Start

May 25, 2021

Primary completion

Sep 30, 2026

Study completion Mar 16, 2027

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
May 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: \- How many participants have an improvement in their symptoms after 52 weeks of treatment? Researchers will answer this and other questions by measuring the symptoms of SLE over time using a variety of scoring tools. These include the SLE Responder Index (SRI), the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K), the British Isles Lupus Activity Group-2004 index (BILAG-2004), and the BILAG-BASED Combined Lupus Assessment (BICLA), among others. Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and SLE have on the quality of life of participants using a group of questionnaires. The study will be done as follows: * After screening, participants will be randomized to receive either a high or low dose of litifilimab, or placebo. A placebo looks like the study drug but contains no real medicine. * All participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks. The treatment period will last 52 weeks. Participants will continue to take their standard of care medications. * Neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo. * There will be a follow-up safety period that lasts up to 24 weeks. * In total, participants will have up to 22 study visits. The total study duration for participants will be up to 80 weeks.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • LitifilimabDrug

    Administered as specified in the treatment arm.

  • PlaceboDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52Time frame: Week 52

Locations

164 sites in 15 countries. Site status is shown where the registry gives one.

  • Tilda Research Birmingham

    Homewood, Alabama

  • Wallace Rheumatic Study Center

    Beverly Hills, California

  • University of Southern California

    Los Angeles, California

  • Providence Facey Medical Foundation

    Mission Hills, California

  • University of California San Diego School of Medicine

    San Diego, California

  • SCLA Management

    Thousand Oaks, California

  • Harbor-UCLA Medical Center

    Torrance, California

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Georgetown University Hospital-Medstar

    Washington D.C., District of Columbia

  • Arthritis & Rheumatic Disease Specialties

    Aventura, Florida

  • Highlands Rheumatology

    Avon Park, Florida

  • Clinical Research of West Florida - Corporate

    Clearwater, Florida

  • Believe Clinical Trials

    Coral Springs, Florida

  • Omega Research Consultants

    DeBary, Florida

  • Centre for Rheumatology, Immunology and Arthritis

    Fort Lauderdale, Florida

  • GNP Research at Mark Jaffe, MD

    Hollywood, Florida

  • Life Clinical Trials

    Margate, Florida

  • Charisma Medical and Research Center

    Miami Lakes, Florida

  • Rheumatology Associates of Central Florida

    Orlando, Florida

  • AdventHealth Medical Group

    Tampa, Florida

  • Vantage Clinical Trials

    Tampa, Florida

  • Rheumatology care of Georgia

    Kennesaw, Georgia

  • Atlanta Research Center for Rheumatology LLC

    Marietta, Georgia

  • Accurate Clinical Research Inc.

    Lake Charles, Louisiana

  • AA MRC LLC Ahmed Arif Medical Research Center

    Flint, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Renown Medical Group

    Reno, Nevada

  • Joseph S. and Diane H. Steinberg Ambulatory Care Center

    Brooklyn, New York

  • Northwell Health Center for Advanced Medicine

    New Hyde Park, New York

  • University of Rochester Medical Center

    Rochester, New York

  • SUNY Upstate Medical Center

    Syracuse, New York

  • Joint and Muscle Research Institute

    Charlotte, North Carolina

  • Medication Management, LLC

    Greensboro, North Carolina

  • OnSite Clinical Solutions, LLC - Charlotte

    Salisbury, North Carolina

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Paramount Medical Research & Consulting, LLC

    Middleburg Heights, Ohio

  • Hightower Clinical

    Oklahoma City, Oklahoma

  • Ramesh C Gupta, MD

    Memphis, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

Showing 40 of 164 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.